Anti-RSV F protein (Nirsevimab) – Fc Muted™

Anti-RSV F protein (Nirsevimab) – Fc Muted™

Product No.: R215

- -
- -
Product No.R215
Respiratory Syncytial Virus
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Human respiratory syncytial virus (hRSV), Respiratory syncytial virus (RSV)
Human IgG1κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Expression Host
HEK-293 Cells
FC Effector Activity
Prefusion RSV F protein
Product Concentration
≥ 5.0 mg/ml
≥95% by SDS Page
≥95% monomer by analytical SEC
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
2-8°C Wet Ice
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Nirsevimab binds the F1 and F2 subunits of the prefusion RSV F protein at a highly conserved epitope in antigenic site Ø.
Antigen Distribution
F protein is found in RSV virion membranes in either an inactive prefusion conformation or an active postfusion conformation.
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection and hospitalization in infants1. RSV F protein is a type I integral membrane protein essential for viral membrane fusion that is highly conserved among isolates of RSV A and B subgroups2. F protein has been investigated as a target for neutralizing antibodies, small molecular antiviral drug development, as a vaccine antigen, and as an antibody target for passive prophylaxis.

F protein is synthesized as an inactive, palmitoylated precursor (F0) and is decorated with N-linked glycans2. Three F0 monomers form a trimer and become activated by a furin-like host protease as they pass through the Golgi. The protease cleaves twice, generating three polypeptides: F2 and F1, which are covalently linked, and pep27, an intervening peptide that dissociates after cleavage. When functional F protein trimer in the virion membrane is triggered, it undergoes a major conformational change from a prefusion to postfusion form. Approximately 25% of isolate specific variability for F protein is found within an antigenic site at the apex of the prefusion trimer (antigenic site Ø), composed of an α-helix from F1 (aa 196–210) and a strand from F2 (aa 62–69).

Nirsevimab is a long-acting, neutralizing recombinant human monoclonal antibody that binds the F1 and F2 subunits of F protein at a highly conserved epitope in antigenic site Ø and locks the RSV F protein in the prefusion conformation, blocking viral entry into the host cell1, 3, 4. In vitro, nirsevimab binds to immobilized human FcγRs (FcγRI, FcγRIIA, FcγRIIB and FcγRIII)3. Protection from infection is thought to be dependent on neutralization activity rather than Fc-mediated effector function based on data from a cotton rat model of RSV infection3. Nirsevimab has been modified with a triple amino acid substitution (YTE) in the Fc region to extend the serum half-life3. Nirsevimab originates from the D25 antibody developed by AIMM Therapeutics and was jointly developed and commercialized by AstraZeneca and Sanofi for the prevention of RSV infection in neonates and infants.

Antigen Details

site A of the RSV-F glycoprotein
NCBI Gene Bank ID
Research Area
Seasonal and Respiratory Infections

References & Citations

1. Hammitt LL, Dagan R, Yuan Y, et al. N Engl J Med. 386(9):837-846. 2022.
2. McLellan JS, Ray WC, Peeples ME. Curr Top Microbiol Immunol. 372:383-104. 2013.
3. Keam SJ. Drugs. 83(2):181-187. 2023.
4. Zhu Q, McLellan JS, Kallewaard NL, et al. Sci Transl Med. 9(388):eaaj1928. 2017.
5. Domachowske JB, Khan AA, Esser MT, et al. Pediatr Infect Dis J. 37(9):886-892. 2018.
6. Zhu Q, Lu B, McTamney P, et al. J Infect Dis. 218(4):572-580. 2018.
7. Griffin MP, Yuan Y, Takas T, et al. N Engl J Med. 383(5):415-425. 2020.
Indirect Elisa Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.